|
CRYZL1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.2385426845517E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
5.08499908846716E-11 |
| Normal-vs-Stage2 |
1.49009999994565E-06 |
| Normal-vs-Stage3 |
9.40449940145527E-11 |
| Normal-vs-Stage4 |
3.22464277502377E-12 |
| Stage1-vs-Stage2 |
8.758600E-01 |
| Stage1-vs-Stage3 |
2.365000E-01 |
| Stage1-vs-Stage4 |
8.023800E-03 |
| Stage2-vs-Stage3 |
5.370000E-01 |
| Stage2-vs-Stage4 |
1.167420E-01 |
| Stage3-vs-Stage4 |
1.831420E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
9.54791801177635E-14 |
| Normal-vs-AfricanAmerican |
1.897700E-02 |
| Normal-vs-Asian |
6.73209999968449E-07 |
| Caucasian-vs-AfricanAmerican |
1.499640E-02 |
| Caucasian-vs-Asian |
1.914380E-01 |
| AfricanAmerican-vs-Asian |
2.433000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.05430109087479E-11 |
| Normal-vs-Female |
1.23150378783521E-11 |
| Male-vs-Female |
4.999000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.09639963774555E-10 |
| Normal-vs-Age(41-60Yrs) |
1.25470001055561E-09 |
| Normal-vs-Age(61-80Yrs) |
9.06309471915279E-11 |
| Normal-vs-Age(81-100Yrs) |
1.354910E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
8.687800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.978800E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.939400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
2.524400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
3.086200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.354200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.023800E-04 |
| Classical-VS-Follicular |
7.697800E-01 |
| Classical-VS-Other |
8.689400E-01 |
| Classical-VS-Normal |
1.83579818013868E-11 |
| Tall-VS-Follicular |
7.098600E-03 |
| Tall-VS-Other |
2.165200E-01 |
| Tall-VS-Normal |
6.01740879346835E-13 |
| Follicular-VS-Other |
8.275400E-01 |
| Follicular-VS-Normal |
3.8174999994478E-07 |
| Other-VS-Normal |
2.094200E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
3.71289998746249E-10 |
| Normal-vs-N1 |
8.85080897461421E-12 |
| N0-vs-N1 |
7.884200E-02 |
|
|
